<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893190</url>
  </required_header>
  <id_info>
    <org_study_id>EG-01-1962-02</org_study_id>
    <secondary_id>2013-000954-23</secondary_id>
    <nct_id>NCT01893190</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <acronym>NEWTON</acronym>
  <official_title>Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edge Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edge Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2a Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety,&#xD;
      Tolerability, and Pharmacokinetic Study Comparing EG-1962 and Nimodipine in Patients with&#xD;
      Aneurysmal Subarachnoid Hemorrhage&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a multicenter, controlled, open label, and randomized, study.&#xD;
&#xD;
      Part 1 of the study is a single dose escalation period to determine the MTD of EG-1962.&#xD;
      During this period, a maximum of 6 dose level cohorts with up to 12 patients per cohort will&#xD;
      be enrolled. In each cohort, patients will be randomly assigned in a ratio of 3:1 to receive&#xD;
      either intraventricular EG 1962 or enteral nimodipine, respectively. The first cohort will&#xD;
      receive 100 mg EG 1962. Upon completion of the dose escalation period, a safe and tolerable&#xD;
      dose will be selected for further study.&#xD;
&#xD;
      Part 2 of the study is a treatment period to assess the safety and tolerability of the&#xD;
      selected dose of EG-1962.&#xD;
&#xD;
      The safety and tolerability of a single intraventricular dose of EG 1962 will be compared to&#xD;
      enteral nimodipine (60 mg given every 4 hours orally or via nasogastric or gastrostomy tube)&#xD;
      for 21 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation Period</measure>
    <time_frame>3 Months</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of intraventricular EG 1962.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK measurements</measure>
    <time_frame>3 Months</time_frame>
    <description>To measure plasma and cerebrospinal fluid (CSF) concentrations of nimodipine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Ruptured Cerebral Aneurysm</condition>
  <condition>Ruptured Berry Aneurysm</condition>
  <arm_group>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nimodipine 60mg q4h for 21 days - oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nimodipine Microparticles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intraventricular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine</intervention_name>
    <description>Based upon Investigator Judgement</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <other_name>Nimodipine Softgel</other_name>
    <other_name>Nimodipine Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine Microparticles</intervention_name>
    <description>Based upon Investigator Judgement</description>
    <arm_group_label>Nimodipine Microparticles</arm_group_label>
    <other_name>EG-1962</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between the ages of 18 to 75 years, inclusive;&#xD;
&#xD;
          -  WFNS Grade 2, 3, or 4 assessed after treatment of the aneurysm but prior to&#xD;
             administration of EG-1962;&#xD;
&#xD;
          -  Ruptured saccular aneurysm confirmed by angiography (catheter or CTA) and treated by&#xD;
             neurosurgical clipping or endovascular coiling;&#xD;
&#xD;
          -  Subarachnoid hemorrhage on baseline CT scan that is diffuse (clot present in both&#xD;
             hemispheres) thick (&gt;4 mm) or thin, or local thick;&#xD;
&#xD;
          -  External ventricular drain (EVD) in place;&#xD;
&#xD;
          -  The patient is able to receive EG-1962 within 60 hours of the onset of subarachnoid&#xD;
             hemorrhage (SAH). Onset of SAH is defined as the time the patient experiences the&#xD;
             first symptom of SAH (e.g., severe headache or loss of consciousness reported either&#xD;
             by patient or by a witness). If found unconscious, the onset of SAH is defined as the&#xD;
             last time the patient was seen at baseline neurological state;&#xD;
&#xD;
          -  Weight &gt;45 kg;&#xD;
&#xD;
          -  Hemodynamically stable after resuscitation with systolic blood pressure (SBP) ≥90 mm&#xD;
             Hg without the use of inotropic agents;&#xD;
&#xD;
          -  Signed informed consent from the patient or the patient's legal representative after&#xD;
             the completion of aneurysm repair and after all study criteria are confirmed; and&#xD;
&#xD;
          -  Female patients of child bearing potential must have negative pregnancy test . Male&#xD;
             patients must agree to use adequate birth control during the study and up to 1 month&#xD;
             after the discontinuation of the study drug treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subarachnoid hemorrhage due to causes other than a saccular aneurysm (e.g., trauma or&#xD;
             rupture of fusiform or infective aneurysm);&#xD;
&#xD;
          -  WFNS Grade 1 or 5 assessed after completion of the aneurysm repair but prior to&#xD;
             administration of EG-1962;&#xD;
&#xD;
          -  Increased intracranial pressure &gt;30 mm Hg in sedated patients lasting &gt;4 hours anytime&#xD;
             since admission;&#xD;
&#xD;
          -  Intraventricular or intracerebral hemorrhage in absence of SAH or with only local,&#xD;
             thin SAH;&#xD;
&#xD;
          -  Angiographic vasospasm prior to aneurysm repair procedure, as documented by catheter&#xD;
             angiogram or CT angiogram;&#xD;
&#xD;
          -  Major complication during aneurysm repair such as, but not limited to, massive&#xD;
             intraoperative hemorrhage, brain swelling, arterial occlusion, or inability to secure&#xD;
             the ruptured aneurysm;&#xD;
&#xD;
          -  Aneurysm repair requiring flow diverting stent or stent-assisted coiling and dual&#xD;
             antiplatelet therapy;&#xD;
&#xD;
          -  Hemodynamically unstable prior to administration of study drug (i.e., SBP &lt;90 mm Hg,&#xD;
             requiring &gt;6 L colloid, or crystalloid fluid resuscitation;&#xD;
&#xD;
          -  Cardiopulmonary resuscitation was required following SAH;&#xD;
&#xD;
          -  Female patients with positive pregnancy test (blood or urine) at screening;&#xD;
&#xD;
          -  History within the past 6 months and/or physical finding on admission of decompensated&#xD;
             heart failure (New York Heart Association Class III and IV or heart failure requiring&#xD;
             hospitalization);&#xD;
&#xD;
          -  Acute myocardial infarction within 3 months prior to the administration of the study&#xD;
             drug;&#xD;
&#xD;
          -  Symptoms or electrocardiogram (ECG)-based signs of acute myocardial infarction or&#xD;
             unstable angina pectoris on admission;&#xD;
&#xD;
          -  Electrocardiogram evidence and/or physical findings compatible with second or third&#xD;
             degree heart block or of cardiac arrhythmia associated with hemodynamic instability;&#xD;
&#xD;
          -  Echocardiogram, if performed as part of standard-of-care before treatment, revealing a&#xD;
             left ventricular ejection fraction &lt;40%;&#xD;
&#xD;
          -  Severe or unstable concomitant condition or disease (e.g., known significant&#xD;
             neurologic deficit, cancer, hematologic, or coronary disease), or chronic condition&#xD;
             (e.g., psychiatric disorder), that, in the opinion of the Investigator, may increase&#xD;
             the risk associated with study participation or study drug administration, or may&#xD;
             interfere with the interpretation of study results;&#xD;
&#xD;
          -  Patients who have received an investigational product or participated in another&#xD;
             interventional clinical study within 30 days prior to randomization. Patients&#xD;
             participating in a non-interventional study that has no bearing on assessment of&#xD;
             EG-1962 or enteral nimodipine can be enrolled per guidelines of the local&#xD;
             Institutional Review Board (IRB) / independent Ethics Committee (IEC).&#xD;
&#xD;
          -  Kidney disease as defined by plasma creatinine ≥2.5 mg/dl (221 μmol/l); liver disease&#xD;
             as defined by total bilirubin &gt;3 mg/dl (51.3 μmol/l); and/or known diagnosis or&#xD;
             clinical suspicion of liver cirrhosis; or Known hypersensitivity to nimodipine or&#xD;
             other dihydropyridine calcium channel antagonists, poly-D, L-lactide-co-glycolide&#xD;
             (PLGA), or hyaluronic acid.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Hanggi</last_name>
    <role>Principal Investigator</role>
    <affiliation>HHU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Cnter</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayfield Clinic Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Division, Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan, Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University, Department of Neurosurgery</name>
      <address>
        <city>Prague</city>
        <zip>16902</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2013</study_first_posted>
  <disposition_first_submitted>January 31, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 5, 2018</disposition_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ruptured saccular aneurysm</keyword>
  <keyword>nimodipine</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>Subarachnoid hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

